Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06298552 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
A Phase 3 study of Myasthenia Gravis and Generalized Myasthenia Gravis, sponsored by argenx.
- Active
- Registry status
- Phase 3
- Development phase
- 119
- Enrollment target
- 20
- Study locations
NCT06298552: Active Phase 3 study of Myasthenia Gravis and Generalized Myasthenia Gravis, sponsored by argenx.
NCT06298552 is a Phase 3 study of Myasthenia Gravis and Generalized Myasthenia Gravis that is active but no longer recruiting, run by argenx. The registered enrollment target is 119 participants, below the 187-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (36% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06298552, a Phase 3 study of Myasthenia Gravis and Generalized Myasthenia Gravis, is active but no longer recruiting, sponsored by argenx.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 119 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to measure the efficacy and safety of efgartigimod IV compared to placebo in participants with Acetylcholine Receptor Binding Antibody (AChR-Ab) seronegative Generalized Myasthenia Gravis (gMG). The study consists of a Part A where participants will be randomized to receive either efgartigimod IV or placebo IV and a Part B where participants completing part A will receive open-label efgartigimod IV. Participants will be in the study for up to (approximately) 2.5 years.
Primary Outcome
The Myasthenia Gravis Activities of Daily Living (MG-ADL) scale is an 8-item instrument used to assess MG symptoms and their effects on daily activities. The total score ranges from 0 (no symptoms) to 24 (most severe symptoms).
Conditions Studied
Interventions
- BIOLOGICAL Efgartigimod IV
- OTHER Placebo IV
Study Locations (20)
Florida
- First Choice Neurology Boca Raton - Boca Raton
- SFM Clinical Research LLC - Boca Raton
- The Neurology Institute / Healthcare Innovations Institute - Coral Springs - Coral Springs
- Neurology Associates PA - Maitland
- Desai Sethi Medical Center - Miami
- Medsol Clinical Research Center Inc - Port Charlotte
- BayCare - St. Anthony's Hospital - St. Petersburg
- University of South Florida (USF) Health - Morsani Center for Advanced Healthcare - Tampa
North Carolina
- University of North Carolina - Chapel Hill - Chapel Hill
- Duke University School of Medicine - Duke Early Phase Clinical Research Unit - Durham
Arizona
- HonorHealth Neurology - Bob Bove Neuroscience Institute - Scottsdale
California
- Loma Linda University Health - Fresno
Georgia
- Wellstar - Augusta University Medical Center - Augusta
Kansas
- Kansas University Medical Center - Kansas City - Fairway
New Jersey
- Rutgers-Robert Wood Johnson Medical School - New Brunswick
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2024-04-16 |
| Est. Completion | 2027-06 |
| Phase | Phase 3 |
What the registry record for NCT06298552 still lists
NCT06298552 is an interventional study that assigns participants to a tested intervention. The registered 119 participants enrollment target is mid-sized for trials with a published cap, below the 187-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (36% lower).
The record links to 4 conditions, with Myasthenia Gravis appearing as the primary indexed condition, and to 2 interventions - of which Efgartigimod IV is the first listed.
NCT06298552 names 20 study sites across 12 states, led by Florida, North Carolina, Arizona.
Frequently Asked Questions
What is clinical trial NCT06298552 about?
NCT06298552 is a clinical study titled "A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis". The primary purpose of this study is to measure the efficacy and safety of efgartigimod IV compared to placebo in participants with Acetylcholine Receptor Binding Antibody (AChR-Ab) seronegative Generalized Myasthenia Gravis (gMG). The study consists of a Part A where participants will be randomized...
What is the current status of trial NCT06298552?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 119 participants. The study started on 2024-04-16. Estimated completion is 2027-06.
What conditions does trial NCT06298552 study?
This clinical trial studies the following conditions: Myasthenia Gravis, Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized.
What interventions are being tested in trial NCT06298552?
The interventions under investigation include: Efgartigimod IV (BIOLOGICAL), Placebo IV (OTHER).
Who is sponsoring clinical trial NCT06298552?
This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06298552 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06298552's enrollment target sits among peer trials
119 14th of 32 higher than 19 of 32 other Myasthenia Gravis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myasthenia Gravis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
Myasthenia Gravis Inebilizumab Trial
ACTIVE NOT RECRUITING · Phase 3
-
Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy
COMPLETED · Phase 3
-
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
RECRUITING
-
The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04870762 · 119 participants · Phase 2
Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
- NCT05559853 · 119 participants
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
- NCT06564389 · 119 participants · Phase 1
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- NCT06742801 · 119 participants · NA
Onyx™ Liquid Embolic IDE Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI